Physician profile
Keith Tyson
NPI 1205815479
$3,717.21
in general payments reported to CMS, 2019-2025
21 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $906 · 2021: $1,361 · 2022: $126 · 2023: $591 · 2024: $286 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $993.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nextremity Solutions INC. | $1,963.12 | 2020-2021 | |
| Organogenesis INC. | $631.19 | 2019-2025 | Puraply, Cygnus Dual, Via Matrix |
| Djo, LLC | $217.23 | 2021-2023 | Donjoy |
| Zimmer Biomet Holdings, INC. | $215.09 | 2019-2021 | |
| Stryker Corporation | $176.11 | 2019-2024 | Augment Injectable |
| Novus Surgical Consultants | $105.57 | 2023 | |
| Pfizer INC. | $75.12 | 2019 | |
| Averitas Pharma INC. | $47.83 | 2024 | Qutenza |
| Medartis INC. | $38.05 | 2023 | Aptus |
| Nevro Corp. | $32.45 | 2023-2024 | Senza |
| Smith+Nephew, INC. | $32.22 | 2019-2020 | |
| Horizon Therapeutics Plc | $31.75 | 2020 | |
| Arteriocyte Medical Systems, INC. | $25.38 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $22.83 | 2025 | |
| Kerecis Limited | $19.83 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kci USA, INC. | $19.01 | 2019 | |
| Ermi LLC | $13.48 | 2019 | |
| Bioventus LLC | $13.30 | 2019 | |
| Shockwave Medical, INC | $13.04 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Depuy Synthes Sales INC. | $12.83 | 2019 | |
| Zyla Life Sciences, INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Tyson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.